Full Analytic Cohort, n = 99 | Radiographic ILD present, n = 73 | |||||
---|---|---|---|---|---|---|
No Significant Decline in DLCO, n = 88 | Decline in DLCO% Predicted ≥ 15 (n = 11) | P | No Significant Decline in DLCO, n = 64 | Decline in DLCO% Predicted ≥ 15, n = 9 | P | |
Age at time of HRCT, yrs | 49.9 (± 10.6) | 47.3 (± 12.6) | 0.53 | 49.0 (± 10.5) | 46.1 (± 13.7) | 0.56 |
Sex, women | 72 (81.8) | 9 (81.8) | > 0.99 | 52 (81.2) | 7 (77.8) | > 0.99 |
Race, White | 66 (75.0) | 9 (81.8) | 0.90 | 45 (70.3) | 7 (77.8) | 0.94 |
Smoker, current or former | 30 (34.1) | 4 (36.4) | > 0.99 | 22 (34.4) | 3 (33.3) | > 0.99 |
GI symptomsa, present | 65 (73.9) | 8 (72.7) | > 0.99 | 47 (73.4) | 7 (77.8) | > 0.99 |
Pulmonary symptomsa, present | 56 (63.6) | 8 (72.7) | 0.80 | 44 (68.8) | 8 (88.9) | 0.39 |
PPI use, current | 49 (55.7) | 6 (54.5) | > 0.99 | 38 (59.4) | 5 (55.6) | > 0.99 |
dcSSc subtype | 38 (43.2) | 8 (72.7) | 0.13 | 31 (48.4) | 7 (77.8) | 0.20 |
SSc disease duration, yrs* | 5.9 (± 8.4) | 3.4 (± 4.6) | 0.14 | 4.6 (± 5.8) | 3.9 (± 5.0) | 0.71 |
Scl-70, positive | 32 (36.4) | 3 (27.3) | 0.80 | 30 (46.9) | 3 (33.3) | 0.68 |
Anticentromere, positive | 16 (18.2) | 0 (0.0) | 0.27 | 3 (4.7) | 0 (0.0) | > 0.99 |
Anti-RNAP3, positive | 24 (27.3) | 4 (40.0) | 0.64 | 17 (26.6) | 3 (33.3) | 0.98 |
ESR | 24 (± 22.0) | 23 (± 20.2) | 0.91 | 23 (± 18.4) | 26 (± 19.9) | 0.72 |
mRSS | 11.0 (± 9.4) | 16.2 (± 8.6) | 0.08 | 11.8 (± 10.1) | 15.4 (± 9.2) | 0.29 |
Medications, any use | 42 (47.7) | 7 (63.6) | 0.50 | 33 (51.6) | 6 (66.7) | 0.62 |
Cyclophosphamide | 5 (5.7) | 0 (0.0) | 0.94 | 5 (7.8) | 0 (0.0) | 0.87 |
Mycophenolate mofetil | 21 (23.9) | 2 (18.2) | 0.97 | 19 (29.7) | 2 (22.2) | 0.94 |
Prednisone | 24 (27.3) | 3 (27.3) | > 0.99 | 18 (28.1) | 2 (22.2) | > 0.99 |
PAH present among those with RHC (n = 56) | 9 (25.0) | 4 (44.4) | 0.46 | 8 (30.8) | 4 (50.0) | 0.57 |
Radiographic ILD, present | 64 (72.7) | 9 (81.8) | 0.78 | 64 (100.0) | 9 (100.0) | NA |
FVC% predicted, baseline | 78 (± 16.6) | 67 (± 14.1) | 0.03 | 76 (± 17.5) | 64 (± 13.6) | 0.04 |
DLCO% predicted, baseline | 58 (± 18.3) | 69 (± 19.3) | 0.10 | 56 (± 18.4) | 62 (± 12.9) | 0.18 |
Digital ulcers, present | 33 (37.5) | 6 (54.5) | 0.45 | 26 (40.6) | 4 (44.4) | > 0.99 |
WED, mm | 17.2 (± 8.6) | 19.5 (± 8.9) | 0.44 | 18.1 (± 8.1) | 20.0 (± 9.6) | 0.58 |
Values are expressed as mean (SD) or n (%).
↵aPulmonary and GI symptoms defined as positive pulmonary and/or GI review of systems in an outpatient rheumatology clinic note within 1 year of HRCT date.
b SSc disease duration defined as the interval between first non-Raynaud SSc symptom and baseline HRCT date. dcSSc: diffuse cutaneous systemic sclerosis; DLCO: diffusing capacity for carbon monoxide (adjusted for hemoglobin); ESR: erythrocyte sedimentation rate; FVC: forced vital capacity; GI: gastrointestinal; HRCT: high-resolution computed tomography of the chest; ILD: interstitial lung disease; mRSS: modified Rodnan skin score; NA: not applicable; PAH: pulmonary arterial hypertension; PPI: proton pump inhibitor; RHC: right heart catheterization; RNAP3: RNA polymerase III; Scl-70: antitopoisomerase I; SSc: systemic sclerosis; WED: widest esophageal diameter.